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Summary: A continuous β-Lactam infusion combined with high-dose oral paracetamol did not 
improve the prognosis of childhood bacterial meningitis in Angola, while compared to conventional 



















In our previous study in Luanda, Angola, initial continuous β-lactam infusion for 24 hours combined 
with oral acetaminophen for 48 hours showed promising results as a new treatment for childhood 
bacterial meningitis. We investigated whether extending this treatment regimen to 4 days would 
improve the outcomes further. 
Methods 
We conducted a randomized, double-blind, parallel-group study at the same hospital in Luanda. 
Children aged 2 months to 15 years presenting to hospital with symptoms and signs of bacterial 
meningitis were randomized to receive, for the first 4 days, a continuous infusion of cefotaxime 
(250mg/kg/day) with simultaneous oral acetaminophen (first dose 30 mg/kg, then 20 mg/kg every 6 
hours), or cefotaxime conventionally as boluses (62.5 mg/kg, 4 times per day) with placebo orally. All 
children received also glycerol orally. The primary outcome was mortality by day 7.  
Results 
In all, 375 patients were included in the study between January 22, 2012 and January 21, 2017. As 
two children succumbed before treatment initiation, 187 vs. 186 participants remained in the 
intervention and control groups, respectively. On day 7, 61/187 (32.6%) children in the intervention 










[95% CI] 0.71 –1.26; absolute risk difference 1.8%, 95% CI -7.8 – 11.4). At discharge from hospital, 
the corresponding numbers were 71/187 (38.0%) and 75/186 (40.3%). 
Conclusions 
Prolonged continuous β-lactam infusion combined with oral acetaminophen did not improve the 
gloomy outcomes of childhood bacterial meningitis in Angola.  















Bacterial meningitis (BM) remains a serious threat to global child health, being the 10th most 
common cause of death in children under 5 years old [1]. The disease burden falls in particular on 
children in resource-poor settings, where the mortality rates may still rise up to 50%, survivors being 
often left with disabling neurological or audiological sequelae. Although vaccination against 
Haemophilus influenzae type b (Hib), several types of Streptococcus pneumoniae, and the essential 
serogroups of Neisseria meningitidis have reduced the burden [2-4], the poor disease outcomes 
urgently call for more effective treatment modalities. 
Dexamethasone, and to a lesser extent, glycerol have been evaluated as adjunctive treatments for 
childhood BM. The results have been controversial [5-8], as their effects likely relate to the study 
environment, causative bacteria, patient age, and likely most importantly, to the clinical condition 
on admission [9]. Neither treatment has, however, significantly reduced the high mortality rate of 
this potentially devastating disease. This said, oral glycerol prevented severe neurological sequelae 
in a large (N= 654) randomized placebo-controlled study in Latin America, the odds ratio (OR) for 
glycerol being 0.31 (95% confidence interval [CI] 0.13–0.76) compared to the placebo recipients [7]. 
Although a similar effect was not obtained later in a smaller study in Malawi [8], the clear results 
from Latin America prevented us, for ethical grounds, from withdrawal of the utilization of glycerol 
in our further BM studies in Africa. 
As β-lactam antibiotics exert time-dependent killing of bacteria, prolonged or continuous infusions 
may optimize the pharmacodynamic performance of these compounds [10]. A continuous infusion 
may also produce other benefits, such as a better controlled inflammatory response due to less 
fluctuating target antibiotic concentrations. We therefore performed a randomized, double-blind, 
and placebo-controlled study at the Hospital Pediátrico David Bernardino in Luanda, Angola in 2005–
2008, in which the effects of initial continuous infusion of cefotaxime were examined [11]. In 










intervention deriving from a large retrospective analysis of bacteremic adult patients in Finland [12]. 
Our main finding from this series of 723 BM patients was that the children receiving cefotaxime 
infusion for 24 hours and oral acetaminophen for 48 hours showed significantly lower mortality, this 
effect starting within the first 24 hours from treatment initiation and lasting for several days [11]. 
Although there was insufficient evidence of a difference at discharge from hospital, this encouraging 
result prompted us to examine our finding further in another study. 
With this background a new trial was carried out at the same institution in Angola, now with a 
prolongation of our modified treatment. We here report the results of this particular investigation. 
 
METHODS 
Study Design and Participants 
This was a single-center, randomized, double-blind, placebo-controlled parallel-group study 
conducted at the Hospital Pediátrico David Bernardino in Luanda, Angola. With its 300 beds and 250 
daily attendees of whom 70 are hospitalised, the institute is the largest pediatric referral center and 
teaching hospital in Angola. The ethics committee of the hospital approved the study protocol on 
19.1.2012.  
The study entry was assessed for all children aged 2 months to 15 years presenting with the 
symptoms and signs suggestive of BM to whom lumbar puncture was performed. The child was 
enrolled, if the cerebrospinal fluid (CSF) appeared cloudy, was positive by Gram staining or showed 
at least 50 leukocytes per mm3. Exclusion criteria included previous known neurological 
abnormalities or hearing impairment, immunosuppression except for HIV infection, active 
tuberculosis, known hepatic disease, or pre-treatment with more than one dose of parenteral 










guardian, whose consent was expressed by a signature or, in case of illiteracy, a finger print. If 
participation was refused, the child was treated as routinely in the hospital. 
The intention-to-treat population comprised all enrolled children, excluding the patients who 
succumbed before the initiation of treatment. The per-protocol analysis included the patients who 
received the allocated treatment and had confirmed BM, defined as a positive CSF culture or PCR; 
those with compatible symptoms and signs of BM and a positive blood culture; or the children with 
compatible symptoms and at least two of the following criteria: CSF pleocytosis ≥ 100 cells/mm3 
(predominantly polymorphs), a positive CSF Gram stain result, a positive CSF latex agglutination test, 
or serum C-reactive protein (CRP) level ≥ 40 mg/L.  
Basic laboratory analyses, bacterial cultures and sensitivity tests were performed at the hospital’s 
laboratory with standard techniques. As of October 2016, CSF samples were also sent to the 
National Institute for Communicable Diseases in Johannesburg, South Africa, for identification of N. 
meningitidis, S. pneumoniae and H.influenzae by PCR [13].  
 
Randomization and Masking  
Randomization was done using a computer generated list in fixed blocks of 20 which allocated the 
participants in a 1:1 ratio. The code was kept in a sealed envelope in the office of the head of the 
hospital, and a copy was sent to the external Data Safety Monitoring Board for the interim analyses. 
For emergency purposes, the opening key was kept sealed also in Helsinki. 
The cards disclosing the specific treatment were kept in sealed envelopes in a box at the hospital 
ward. Once the attending physician had included a patient in the study, an otherwise non-
participating study nurse opened the next envelope, prepared the medications and placebos as 
advised, and gave the preparations for 96 hours (4 days). Thus, the patients, guardians, attending 










For further masking, all children received both infusions and boluses intravenously for the entire 4-
day course. Since the ready-to-use cefotaxime is slightly yellowish liquid, yellow i.v. lines (Becton-
Dickinson GmbH, Art.No. 300326) and black 50 ml syringes (B Braun, Ref No 8728828F) were used 
with a foil covering on the 3-way stopcock’s (B Braun Smallbore T-Port Extension Set, Ref No 471954) 
short end which leads to the skin-penetrating needle. This setup allowed the same one line for the 
antimicrobial and placebo administrations, each always given as infusion or boluses. 
As black syringes and yellow i.v. lines were used, saline could be used as a placebo preparation for 
cefotaxime, no matter how administered. The oral acetaminophen solution from effervescent 
tablets looked like plain water once the bubbles had disappeared. Being practically tasteless, regular 
drinking water served as its placebo. 
 
Procedures 
All children were treated with cefotaxime in a dose of 250 mg/kg/24 hours for seven days. For the 
first four days, the children were randomized to receive the agent as a continuous intravenous 
infusion with high-dose acetaminophen orally (first dose 30 mg/kg, then 20 mg/kg every 6 hours for 
4 full days), or as conventional intravenous boluses (62.5 mg/kg every 6 hours) with placebo orally. 
To prevent degradation of the antibiotic, the daily dose of cefotaxime was administered as two 12-
hour infusions (125mg/kg each). The dissolved acetaminophen (Panadol®) tablets formed a solution 
with 10 mg/ml of acetaminophen. 
Based on our previous studies [7, 11], all children were given oral glycerol (6.0g/kg per day divided 
into 4 equal doses, maximum dose of 25g) for 2 days. Antipyretics (besides scheduled 
acetaminophen as part of the intervention) were avoided. If hyperpyrexia or pain required 
medication, ibuprofen was given at a dose of 15mg/kg twice daily. Seizures were treated as was the 










derivatives were used. A blood transfusion (10ml/kg) was administered to children with a 
haemoglobin level < 50 g/L, and sometimes also if considered clinically relevant. Fluid therapy aimed 
at normovolemia. Blood glucose was monitored four times daily, and hypoglycaemia was corrected 




The primary outcome measure was mortality by day seven in hospital. The secondary outcome 
measures included later in-hospital mortality, the composite outcomes of death or severe 
neurological sequelae (hydrocephalus, severe psychomotor retardation, quadriparesis, or blindness), 
and death or any neurological sequelae (hemi- or monoparesis, ataxia, or psychomotor retardation 
of any degree, besides the above-mentioned sequelae). The secondary neurological outcomes were 
recorded on day seven and at discharge from hospital.  
We also aimed at measuring the hearing impairment quantitatively, but due to economical and 
practical constraints, precise audiological measurements were eventually performed only in a 
handful of survivors. Adverse events and the safety of our treatment were assessed as part of the 
detailed follow-up of all participants. 
 
Statistical Analysis 
Based on our previous study in Angola [11], we assumed to attain a 13% decrease in mortality with 
our intervention in patients with confirmed BM. Accepting a 5% error after adjustment for multiple 
testing in one-tailed test with a power of 80%, at least 165 patients were required in each treatment 










malnutrition and malaria, we intended to enrol 400 patients. An external Data Safety Monitoring 
Board obtained the 7-day results after each 100 patients had been evaluated. Had an indisputable 
significance between the treatment modalities been found, the board would have interrupted 
enrolment for ethical reasons. 
Differences between the study groups regarding the in-hospital clinical course were assessed using 
chi-square test or Mann-Whitney U test, as appropriate. Potential differences between the study 
groups in terms of the primary and secondary outcomes were analysed by chi-square test, or in the 
case of low expected cell values in the 2x2 table, Fisher’s exact test. The treatment effects on the 
primary and secondary outcomes were presented as risk ratios with 95% confidence intervals (CI); 
the absolute risk difference and its confidence intervals were obtained using a 2-sample z-test. 
Kaplan-Meier analysis and the log-rank test were used when comparing the time of death and 
potential differences in survival, while treatment interactions between subgroups were examined 
with logistic regression analysis. All subgroup analyses were predefined in the study protocol. P-
values < 0.05 were considered statistically significant, and to detect potential adverse effects of the 
treatments, all analyses were conducted using a two-sided hypothesis. Furthermore, differences 
between the participants of the current study and our previous trial in Luanda were assessed using 
chi-square test or Mann-Whitney U test.  
 
RESULTS 
Recently commenced Hib and pneumococcal vaccinations in Angola had reduced the incidence of 
BM to the extent that patient enrolment was extended to the predefined maximum of five years 
(from January 22, 2012 to January 21, 2017). In all, 1128 children were assessed for eligibility, 753 










succumbed before treatment initiation, 373 children comprised the intention-to-treat population 
(Figure 1). 
Of those, 43 were protocol violators: in 16 cases paralytic ileus prevented oral administration, while 
the remaining 27 treatment failures were due to insurmountable practical difficulties such as 
dysfunctional intravenous lines. The number of treatment failures was similar in both treatment 
arms (Figure 1). Finally, our strict criteria for confirmed BM excluded additional 126 participants 
from the per-protocol population which ultimately comprised 204 children (Figure 1). 
As summarized in Table 1, the patient characteristics and laboratory results proved similar in both 
groups. Since the median prehospital duration of illness was five days, the child was usually severely 
ill: 67% had suffered from seizures and some 1/3 showed focal neurological signs on admission. 
Malnutrition was common, and according to the WHO reference [14], 26% of the children presented 
with a weight-for-age Z-score under -2 SD. The causative agent was identified in 152/373 (41%) of 
cases, S. pneumoniae being the most common bacterium (Table 1). Interestingly, other not-so-
common agents such as Klebsiella spp. (n = 6) and Proteus spp. (n = 6) were also detected. 
After 7 days of treatment, 125 (34%) of the 373 patients had died. The composite outcomes of death 
or severe neurological sequelae (SeNeSe), and of death or any neurological sequelae (AnNeSe) were 
observed in 45% (155/345) and 54% (182/334) of the series, respectively (Table 2). As 21 patients 
succumbed after the first week, the final fatality rate increased to 39%. At discharge, 47% (175/369) 
of patients had either died or survived with severe neurological sequelae. Adding any neurological 
sequelae to the calculation, the proportion rose to 54% (193/360) (Table 2).  
The day-7 mortality and the death rate at discharge were similar in the treatment groups (Table 2). 
Nor did their composite outcomes differ, albeit the effect of the interventional treatment seemed 










2). Overall, our prolonged modified treatment did not show significant benefits, as depicted in Figure 
2. 
Since the prognosis of BM differs substantially in different populations, we also analysed certain 
predefined subgroups (Table 3). While the overall mortality varied largely, the given treatment did 
not relate to improved survival in any subgroup. Regarding the course of illness on the ward, 
ibuprofen was given more often in the control group, likely due to the higher need of antipyresis 
among these children (Table 4).  
Potential adverse events of the treatments were registered as part of the normal follow-up. 
Furthermore, any abnormal signs of illness, not compatible with the diagnosis of meningitis, were 
registered in the follow-up sheet. In this regard, the groups did not differ. 
 
DISCUSSION 
No benefit from using prolonged four-day infusion of cefotaxime combined with oral acetaminophen 
was found in this trial on childhood BM in Luanda, Angola. Mortality and neurological sequelae 
remained the same regardless of whether cefotaxime with or without oral acetaminophen was 
administered conventionally in boluses every 6 hours, or as continuous infusion for four days. 
Our rationale for using continuous infusion of antibiotic in BM relies, in addition to the 
pharmacodynamic advantages, also on relieving the initial inflammatory burst triggered by the 
strongly bacteriolytic β-lactam in the central nervous system. The basis for using oral acetaminophen 
at the same time laid, on the other hand, in the large retrospective study in which it significantly 
associated with decreased mortality in adult bacteraemia [12]. In our previous trial in Angola [11], an 
initial 24-hour cefotaxime infusion with the simultaneous 48-hour oral acetaminophen reduced BM 










thus logic to assume that prolonging our modified treatment would lead to permanent mortality 
decrease. As disappointing as it was, this was not the case here: no benefit was achieved with such a 
treatment prolongation. 
To find explanations for this discrepancy, we searched for differences between these two patient 
populations (Supplementary Table 1 in Supplementary Material). Shortly, participants in this study 
arrived to hospital more severely ill, were more frequently malnourished and dehydrated, and 
clearly differed in etiology. The role of Hib meningitis was dramatically reduced while the proportion 
of less common meningitis agents increased, and more participants were left with an unknown 
bacterial etiology. The participants of this study were also older and had received pre-admission 
antibiotics more often, while compared to the participants of our previous trial. 
Our interpretation is that many children here had already passed the moment when the new 
treatment would have had a potential to help the patient [15]. Of special note is our earlier finding 
that in childhood BM, the presenting condition surpasses all other cofactors predicting death, being 
as a single covariant even more important than the causative agent as such [9]. The major changes in 
bacterial etiology might also contribute to the discrepancy between our two trials. 
Some correlation to the adult studies, in which continuous or prolonged antibiotic infusions have 
also led to non-consistent results, might here be justifiably drawn [16]. Slow, continuous infusion 
probably performs best in some patient subpopulations whose identification poses a challenge to 
future trials.  
Successful Hib and pneumococcal vaccinations in Angola hindered our collection of the targeted 
minimum of 165 confirmed BM cases in both study groups. The large heterogeneous group, which 
was excluded from the per-protocol analysis, comprised children with diseases such as tuberculous 
meningitis, cerebral malaria and rabies – and among them there probably were some cases of 










measurements in survivors, which prevented us from evaluating the treatment’s possible effect on 
hearing impairment.  
All these shortcomings no doubt lessened the value of our observations. This said, however, our 
experience is a truthful description of the circumstances prevailing today in many sites of sub-
Saharan Africa. Acknowledging the frequent lack of diagnostic tools and the challenging differential 
diagnostics, our intention-to-treat population probably well represents children who are treated for 
BM in these settings. Therefore, in spite of the large drop-out rate, we believe our main result 
remains valid and applicable for this kind of patient populations. 
Our study underlines the gloomy prognosis of childhood BM in Angola. A continuous antibiotic 
infusion and oral acetaminophen did not improve the outcome of these severely ill children, who 
often came late for treatment. Since the prehospital delay is unbearably long, more efforts should 
be put into the parents’ knowledge of the symptoms and signs of BM. Also better availability of 
healthcare would hasten the adequate treatment. Large-scale vaccinations against the relevant 
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Table 1. Baseline patient characteristics of the intention-to-treat population 
Characteristic 
Bolus + placebo  
(N = 186) 
Infusion + acetaminophen  
(N = 187) 
Age in months (range) 31 (1-161) 28 (2-177) 
Male sex  115 (62%) 101 (54%) 
Weight-for-age under -2SDa 48 / 185 (26%) 48 / 186 (26%) 
Duration of symptoms > 3 daysa 116 / 181 (64%) 136 / 184 (74%) 
Previous antibioticsa 73 / 165 (44%) 95 / 170 (56%) 
Seizures before admissiona 122 / 175 (70%) 116 / 178 (65%) 
Glasgow Coma Scale score 11 (8-15) 12 (9-15) 
Focal neurological signsa 53 / 181 (29%) 60 / 176 (34%) 
Another focus of infectiona 46 / 169 (27%) 62 / 178 (35%) 
Dyspnoeaa 111 / 177 (63%) 100 / 181 (55%) 
Dehydrationa 43 / 183 (23%) 46 / 182 (25%) 
Blood test results: 
  
Hb (g/L)b 73 (60-92) 74 (62-89) 
Leukocyte count (x 109/L)b 15.1 (9.0-21.0) 13.7 (8.8-19.7) 
CRP (mg/L)b 160 (96 - >160) 160 (91 - >160) 
Malaria test positivec 51 / 186 (27%) 40 / 187 (21%) 










CSF test results: 
Leukocyte count (x 106/L)  495 (130-2770) 800 (140-2289) 
Protein level (mg/dL) 197 (123-265) 187 (110-250) 
Glucose level (mmol/L)  0.9 (0.5-2.7) 1.1 (0.5-2.4) 
Causative agent 
Streptococcus pneumoniae (n=73) 38 (20%) 35 (19%) 
Neisseria meningitidis (n=37) 21 (11%) 16 (9%) 
Haemophilus influenzae (n=7) 4 (2%) 3 (2%) 
Other bacteria (n=39) 16 (9%) 23 (12%) 
Unknown (n=217) 107 (58%) 110 (59%) 
Data are presented as number of patients (%) or median value (IQR), unless otherwise indicated.  
aDenominator indicates the number of patients of whom the information was available 
bHighest (CRP, leukocyte count) and lowest (Hb) value of days 1-2 



















Table 2. The two treatment modalities versus the risk of adverse outcomes in the intention-to-treat and per-protocol populations 
Outcome 
Infusion + acetaminophen, 
% (n) 
Bolus + placebo, % (n) Risk Ratio (95% CI) 
Absolute risk difference, % 
(95% CI)a 
Intention-to-treat 
Day 7 death 32.6% (61/187) 34.4% (64/186) 0.95 (0.71 – 1.26) 1.8 (-7.8 – 11.4) 
Death at discharge 38.0% (71/187) 40.3% (75/186) 0.94 (0.73 – 1.21) 2.3 (-7.6 – 12.2) 
SeNeSe or death, day 7  46.5% (80/172) 43.4% (75/173) 1.07 (0.85 – 1.36) 3.1 (-7.4 – 13.6) 
SeNeSe or death, at discharge  48.4% (90/186) 46.4% (85/183) 1.04 (0.84 – 1.29) 2.0 (-8.2 – 12.2) 
AnNeSe or death, day 7  57.8% (96/166) 51.2% (86/168) 1.13 (0.93 – 1.38) 6.6 (-4.1 – 17.3) 
AnNeSe or death, at discharge 57.5% (104/181) 49.7% (89/179) 1.16 (0.95 – 1.40) 7.8 (-2.5 – 18.1) 
Per-protocol 
Day 7 death 30.6% (33/108) 34.4% (33/96) 0.89 (0.60 – 1.32) 3.8 (-9.1 – 16.7) 
Death at discharge 33.3% (36/108) 37.5% (36/96) 0.89 (0.61 – 1.29) 4.2 (-8.9 – 17.3) 










SeNeSe or death, at discharge  42.6% (46/108) 45.2% (42/93) 0.94 (0.69 – 1.29) 2.6 (-11.2 – 16.4) 
AnNeSe or death, day 7  53.1% (51/96) 54.8% (46/84) 0.97 (0.74 – 1.27) 1.7 (-12.9 – 16.3) 
AnNeSe or death, at discharge 50.0% (52/104) 50.6% (45/89) 0.99 (0.75 – 1.31) 0.6 (-13.6 – 14.8) 
aThe absolute risk difference and its confidence intervals were obtained using a 2-sample z-test. 

































Age Pa Pb 
Age < 12 months (n = 107)  33% (18/54) 34% (18/53) 0.95 
0.72 
Age ≥ 12 months  (n = 265)  35% (46/132) 32% (42/133) 0.57 
Presenting conditionc 
 
GCS < 12 (n = 178) 49% (46/94) 49% (41/84) 0.99 
0.74 
GCS ≥ 12 (n = 181) 20% (17/87) 17% (16/94) 0.66 
Duration of illness before hospital admissiond 
Ill ≤ 3 days (n = 113)  22% (14/65) 19% (9/48) 0.72 
0.93 
Ill > 3 days (n = 252)  41% (47/116) 38% (51/136) 0.62 
Weight-for-age Z-scoree 
Slightly malnourished or normal (≥ 
-2 SD) (n = 275) 
31% (43/137) 29% (40/138) 0.66 
0.82 
Severely malnourished (< -2 SD) (n 
= 96) 
42% (20/48) 42% (20/48) 1.00 
Bacterial etiology 
Streptococcus pneumoniae (n = 73) 45% (17/38) 34% (12/35) 0.36 
0.40 
































These subgroup analyses were predefined, and conducted within the intention-to-treat population. 
aObtained using a chi-squared test within the subgroup 
bCalculated, using logistic regression analysis, for interaction between each variable and the 
treatment 
cData on the GCS score was missing from 14 participants 
dDuration of illness unknown in 8 participants 
eInformation missing from 2 participants 


















Duration of fever (days)  2 (1-3) 2 (1-3) 1.00 
Duration of GCS < 15 (days) 3 (1-5) 2 (1-5) 0.45 
Seizures 
130 / 185 
(70%) 
123 / 185 (67%) 0.43 
Focal neurological signs 76 / 181 (42%) 79 / 175 (45%) 0.55 
Duration of survivors’ hospital stay 
(days) 
12 (10-17) 14 (10-20) 0.14 
Non-study treatments given 
 
Supplementary oxygen 76 / 186 (41%) 76 / 186 (41%) 1.00 
Blood transfusion 44 / 186 (24%) 47 / 187 (25%) 0.74 
Anticonvulsive medication 89 / 185 (48%) 87 / 186 (47%) 0.80 
Malaria treatment 92 / 186 (50%) 90 / 187 (48%) 0.80 
Ibuprofen, during first four days 71 / 185 (38%) 49 / 187 (26%) 0.01 
Additional antibiotic treatment  
(after first seven days) 
70 / 184 (38%) 79 / 186 (43%) 0.39 
Tuberculosis treatment 11 / 185 (6%) 15 / 187 (8%) 0.43 
Data are displayed as number of patients (%) or median value (IQR). 
aObtained using chi-square test or Mann-Whitney U test, as appropriate 


















Figure 1. Flowchart of patient inclusion 
Figure 2. Mortality curves for intention-to-treat (A) and per-protocol (B) populations, 
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